Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124788 | 0.82 | FBP1 (0.41) | AAK1PTGDR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30093499 | 0.82 | FBP1 (0.41) | AAK1PTGDR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21571685 | 0.80 | PTGDR2 (0.40) | AAK1PTGDR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23124466 | 0.79 | AAK1 (0.47) | AAK1PTGDR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL25798391 | 0.79 | AAK1 (0.35) | AAK1DGAT1PTGDR2NPC1RAB9A | |
| SCHEMBL23124792 | 0.77 | FBP1 (0.41) | AAK1SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL22688970 | 0.77 | HSD11B1 (0.44) | USP30PTGDR2 | |
| SCHEMBL31085069 | 0.75 | NOTUM (0.40) | AAK1DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3988132 | 0.75 | AAK1 (0.44) | AAK1DGAT1PTGDR2NPC1RAB9A | |
| SCHEMBL5727051 | 0.74 | PPARA (0.45) | NPC1RAB9ASMN1; SMN2RECQLMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021055936-A1 | SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN−PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | AAK1 3144/4885USP30 3152/4885DGAT1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.